Time to Revisit a Voluntary FDA Comparative Effectiveness Pathway.
Ther Innov Regul Sci
; 55(4): 643-645, 2021 07.
Article
em En
| MEDLINE
| ID: mdl-33569676
ABSTRACT
Given the renewed policy focus on drug pricing and pharmaceutical innovation, this article examines the historical backdrop of efforts to integrate comparative effectiveness research into the FDA drug review process. Noting previous policy efforts over a decade ago, we characterize industry challenges and suggest a path forward.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Ther Innov Regul Sci
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Estados Unidos